Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

A session was presented at the 2026 Maui Derm Hawaii conference titled ‘Best of the Best at Maui Derm,’ during which its 2 presenters highlighted recent data in the psoriasis treatment space on emerging therapeutic agents.1

Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, presented this talk. Stein Gold, who previously touched on these findings in an HCPLive interview, was asked in this video about what stood out in the panel discussion about improving early recognition of psoriatic arthritis (PsA).

“When we think about our psoriasis patients, we have to remember that this is a systemic disease, and psoriatic arthritis is one of those manifestations that occurs quite commonly in our psoriasis patients,” Stein Gold explained.

Stein Gold noted during certain times, clinicians should have the potential for PsA development at front of mind. Such patients will specifically have scalp involvement or nail involvement. These patients may require substantial attention in terms of early PsA detection.

Later, Stein Gold was asked about practicing clinicians trying to navigate an increasingly complex therapeutic landscape. Specifically, she was asked which guiding principles she would emphasize when choosing among new and established psoriasis treatments.

“It can be very confusing when we look at our current options and our new options for psoriasis patients, but I think we really owe it to ourselves and to our patients to understand what's going on with each new drug,” Stein Gold explained. “We don't have to know every single drug, but we should get to know drugs in particular categories. Get to know a really good IL-23 drug and IL-17 drug, maybe a TNF-inhibitor, that you're comfortable with. Then let's look at the newer oral agents. Let's look at the TYK2 inhibitors.”

To find out more on the topics covered here, view Stein Gold’s full video above. For more from Maui Derm, view the latest conference coverage.

The quotes used in this interview summary were edited for clarity.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

References

1. Stein Gold L, Hawkes J. Best of the Best at Maui Derm. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

2. Armstrong AW, Gooderham M, Papp K, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Oct 1;160(10):1066-1074. doi: 10.1001/jamadermatol.2024.2701. PMID: 39167366; PMCID: PMC11339701.